non-small cell lung cancer
Conditions
Interventions
AdministrationofTheracurmin and erlotinib for 8 weeks. Dosage of erlotinib 150mg per day,Theracurmin, 1 cohort, 360mg per day.
Sponsors
Saitama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)histological,cytological diagnosis of non-small cell lung cancer 2)failure of previous treatment or 1st line erlotinib 3)compliant with oral medication 4)failure of standard treatments or first line erlotinib 4)lesion that can be evaluated by RECIST 5)PS0to2 6)can be admitted for the first 2 weeks of treatment 7)age over 20 8)adequate general condition 9)Patients expected of 3 months or more survival 10)approximately four weeks or more must pass from the prior treatment 11)Written consent
Exclusion criteria
Exclusion criteria: 1)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2)plueral, peritoneal, or pericardial effusion requiring drainage 3)active infection 4)unable to take oral medication 5)symptomatic eye disorders 6)pregnant or lactating 7)symptomatic brain metastasis 8)other malignancies 9)uncontrolled diabetes 10) active complications 11)patients whom physicians judged to be unsuitable for enrollment for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety | — |
Countries
Japan
Contacts
Public ContactMitsuo Nakayama
Saitama Medical Center general thoracic surgery
Outcome results
None listed